JAC Advance Access originally published online on June 26, 2007
Journal of Antimicrobial Chemotherapy 2007 60(3):470-482; doi:10.1093/jac/dkm226
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Review |
Class A carbapenemases
Department of Clinical Microbiology, 9301, Rigshospitalet, National University Hospital, Copenhagen, Denmark
* Correspondence address. Department of Clinical Microbiology, 9301, Juliane Mariesvej 22, DK-2100 Copenhagen O, Denmark. Tel: +45-26-37-76-60; Fax: +45-35-45-64-12; E-mail: jawalras{at}mail.tele.dk
Carbapenems, such as imipenem and meropenem, are most often used to treat infections caused by enterobacteria that produce extended-spectrum ß-lactamases, and the emergence of enzymes capable of inactivating carbapenems would therefore limit the options for treatment. Carbapenem resistance in Enterobacteriaceae is rare, but class A ß-lactamases with activity against the carbapenems are becoming more prevalent within this bacterial family.
The class A carbapenemases can phylogenetically be segregated into six different groups of which four groups are formed by members of the GES, KPC, SME, IMI/NMC-A enzymes, while SHV-38 and SFC-1 each separately constitute a group.
The genes encoding the class A carbapenemases are either plasmid-borne or located on the chromosome of the host. The blaGES genes reside as gene cassettes on mainly class I integrons, whereas the blaKPC genes and a single blaIMI-2 gene are flanked by transposable elements on plasmids.
Class A carbapenemases hydrolyse penicillins, classical cephalosporins, monobactam, and imipenem and meropenem, and the enzymes are divided into four phenotypically different groups, namely group 2br, 2be, 2e and 2f, according to the Bush–Jacoby–Medeiros classification system. Class A carbapenemases are inhibited by clavulanate and tazobactam like other class A ß-lactamases.
Keywords: class A ß-lactamases , carbapenem resistance , Enterobacteriaceae , Pseudomonas aeruginosa
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. Frase, Q. Shi, S. A. Testero, S. Mobashery, and S. B. Vakulenko Mechanistic Basis for the Emergence of Catalytic Competence against Carbapenem Antibiotics by the GES Family of {beta}-Lactamases J. Biol. Chem., October 23, 2009; 284(43): 29509 - 29513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Kitchel, D. R. Sundin, and J. B. Patel Regional Dissemination of KPC-Producing Klebsiella pneumoniae Antimicrob. Agents Chemother., October 1, 2009; 53(10): 4511 - 4513. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Kitchel, J. K. Rasheed, J. B. Patel, A. Srinivasan, S. Navon-Venezia, Y. Carmeli, A. Brolund, and C. G. Giske Molecular Epidemiology of KPC-Producing Klebsiella pneumoniae Isolates in the United States: Clonal Expansion of Multilocus Sequence Type 258 Antimicrob. Agents Chemother., August 1, 2009; 53(8): 3365 - 3370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Toye, S. Krajden, M. Fuksa, D. E. Low, and D. R. Pillai Carbapenem resistance in Canada Can. Med. Assoc. J., June 9, 2009; 180(12): 1225 - 1226. [Full Text] [PDF]
|
|
|
|
 |
|
 F. Pasteran, T. Mendez, L. Guerriero, M. Rapoport, and A. Corso Sensitive Screening Tests for Suspected Class A Carbapenemase Production in Species of Enterobacteriaceae J. Clin. Microbiol., June 1, 2009; 47(6): 1631 - 1639. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Samuelsen, U. Naseer, S. Tofteland, D. H. Skutlaberg, A. Onken, R. Hjetland, A. Sundsfjord, and C. G. Giske Emergence of clonally related Klebsiella pneumoniae isolates of sequence type 258 producing plasmid-mediated KPC carbapenemase in Norway and Sweden J. Antimicrob. Chemother., April 1, 2009; 63(4): 654 - 658. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Endimiani, A. M. Hujer, F. Perez, C. R. Bethel, K. M. Hujer, J. Kroeger, M. Oethinger, D. L. Paterson, M. D. Adams, M. R. Jacobs, et al. Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA J. Antimicrob. Chemother., March 1, 2009; 63(3): 427 - 437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Peirano, L. M. Seki, V. L. Val Passos, M. C. F. G. Pinto, L. R. Guerra, and M. D. Asensi Carbapenem-hydrolysing {beta}-lactamase KPC-2 in Klebsiella pneumoniae isolated in Rio de Janeiro, Brazil J. Antimicrob. Chemother., February 1, 2009; 63(2): 265 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Petrella, N. Ziental-Gelus, C. Mayer, M. Renard, V. Jarlier, and W. Sougakoff Genetic and Structural Insights into the Dissemination Potential of the Extremely Broad-Spectrum Class A {beta}-Lactamase KPC-2 Identified in an Escherichia coli Strain and an Enterobacter cloacae Strain Isolated from the Same Patient in France Antimicrob. Agents Chemother., October 1, 2008; 52(10): 3725 - 3736. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Wright and E. H. Eiland III Current Perspectives on Extended-Spectrum Beta-Lactamase-Producing Gram-Negative Bacilli Journal of Pharmacy Practice, October 1, 2008; 21(5): 338 - 345. [Abstract] [PDF]
|
|
|
|
|
|
A. Endimiani, L. L. Carias, A. M. Hujer, C. R. Bethel, K. M. Hujer, F. Perez, R. A. Hutton, W. R. Fox, G. S. Hall, M. R. Jacobs, et al. Presence of Plasmid-Mediated Quinolone Resistance in Klebsiella pneumoniae Isolates Possessing blaKPC in the United States Antimicrob. Agents Chemother., July 1, 2008; 52(7): 2680 - 2682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Dortet, I. Radu, V. Gautier, F. Blot, E. Chachaty, and G. Arlet Intercontinental travels of patients and dissemination of plasmid-mediated carbapenemase KPC-3 associated with OXA-9 and TEM-1 J. Antimicrob. Chemother., February 1, 2008; 61(2): 455 - 457. [Full Text] [PDF]
|
|